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Abstract
The field of biomarkers is a growing one, particularly in osteoarthritis
(OA). OA is the most common disabling condition in older persons
and a major cause of morbidity. While the debate continues about
which of the involved tissues – cartilage, bone or synovium – is the
most important in OA aetiology, there is no doubt that the three
develop abnormalities in concert; perhaps a truly useful biomarker
will reflect just that. While efforts continue to identify reliable
biomarkers useful for characterising the status, prognosis and
measurement of treatment response in OA, combining existing
biomarkers to improve their accuracy looks promising.
Osteoarthritis (OA) is the most common joint condition in
older persons and is among the leading causes of disability in
the developed world. The study of biomarkers is a growing
field, particularly in OA, a condition that finds itself pretty
isolated among the diseases seen in rheumatology – with
little in the way of treatment other than joint replacement
surgery. A condition as common as OA is in urgent need of
disease-modifying treatment (DMOAD). As populations
become heavier and more aged, OA is predicted to increase
markedly in prevalence. The identification of biomarkers is
one way to accelerate drug discovery and drug trials, the
crucial rate-limiting step in bringing a novel therapeutic agent
to the market. Biomarkers may be derived from all forms of
biological variables, be they biochemical compounds, genetic
loci or RNA fragments. Current biomarkers of interest in OA
reflect the tissues involved in the pathology, from cartilage
(for example, collagenous, type II collagen; and non-
collagenous, cartilage oligomeric matrix protein) to bone (for
example, collagenous, type I collagen; non-collagenous,
osteocalcin) and synovium (for example, type III collagen).
Much biomarker research is, therefore, directed toward
optimising the quantitation of changes in cartilage volume and
turnover. Another advantage of combining biomarkers is the
capture of information on both incidence of features and
turnover of tissues. In the paper by Erik Dam and colleagues in
the previous issue of Arthritis Research & Therapy, the authors
combined a biochemical marker with magnetic resonance
imaging (MRI) features in an attempt to identify three important
disease features: diagnosis, prognosis and efficacy of
intervention [1]. MRI is used increasingly to document the
various pathological features of OA and is unquestionably
superior to plain radiographs. MRI allows the appreciation not
only of joint space narrowing (representing cartilage loss) and
osteophyte growth, but also of changes within bone (bone
marrow lesions) and far greater capacity for assessing cartilage
loss in minute detail by, for example, morphometric three-
dimensional analysis. Automated methods have been
developed which quantify cartilage using this technique,
although further validation is required. For an excellent review of
biomarkers in OA, see Rousseau and Delmas [2].
Combining markers is intuitively the next step for a number of
reasons and it is a route being adopted in a number of fields,
not just in biomarkers; it makes good financial as well as
scientific sense to use what has already been identified. No
single biomarker will be a perfect descriptor of OA any more
than one single pathological feature encapsulates the
coordinated changes in the three tissues along with the
cytokines released [3]. Biomarkers have a number of uses: in
selecting patients for recruitment to drug trials, in early
diagnosis, in prognosis and in measuring response to
treatment. If bringing a new drug to market costs, say,
£10 million (US $16.3 million), then every month of a trial
becomes crucial to the health economics of a pharmaceutical
firm: if trials are too expensive, they won’t be carried out and
potential DMOADs will be lost. Because of the chronic and
variable nature of OA, new methods are needed to optimise
the selection of patients for trials and as outcome measures  –
in short, any route by which the long course of OA can be
abbreviated into a more cost-effective time frame.
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In the report of Dam and colleagues, subjects with normal
health and with knee OA underwent baseline plain radiograph
and MRI, demographic data collection, blood and urine
collection (for markers of cartilage turnover) and then repeat
MRI at 21 months. The final analysis group comprised 287
knees scored conventionally using Kellgren and Lawrence as
well as for knee size using the tibial plateau and MRI scans
from a 0.18-Tesla extremity scanner that gave fully automated
measures of volume, surface area and cartilage homogeneity.
Biomarkers (image- and urine-derived) were judged by their
ability at baseline to discriminate between cases and non-
cases (KL >1 versus KL ≤1) and for prognostic value in order
to separate the progressors from non-progressors. Receiver-
operator curves of individual and combined biomarkers were
generated. Results were expressed as odds ratio and area
under the curve and so conformed to BIPED (burden of
disease, investigative, prognostic, efficacy of intervention and
diagnostic) recommendations [4].
As the authors comment, the use of the current suboptimal
method for determining OA radiographically is a weakness
and only early OA is included in the study. Results showed a
5% to 10% improvement in prediction using combined
versus single biomarkers – a definite improvement on existing
biomarkers. This is an important principle and should provide
the stimulus for other groups to look in their biomarker
collections and combine markers to optimise predictive value.
DMOAD research over the next decade should be
approached with optimism – millions of patients are waiting
for something to alter the course of their disease.
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